03 Sep StimulusBio
StimulusBio enables quantitative control of immune cell activation and expansion. Our patent-pending Programmable Cellular Interface (sbPCI™) technology presents stimulatory, co-stimulatory, and signaling molecules in a defined, tunable format, allowing researchers to precisely control signal identity, density, and distribution without genetic modification. By anchoring custom bioactive units directly to a presenting cell’s membrane in under one hour, sbPCI transforms signal presentation into a design variable and shortens development timelines from months to days. The CellPilot™ portfolio supports CAR-T, TIL, NK, CAR-NK, feeder cell replacement, and stem cell applications through a flexible, biocompatible platform for designing and optimizing cell therapies. It integrates with existing workflows, bioreactors, and instruments while reducing reliance on genetically modified feeder lines and costly mediators. We are currently offering early-access products and seeking additional collaborators interested in advancing next-generation immune and stem cell technologies.